IRIS UniCatt

Ponziani, Francesca Romana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.329
AS - Asia 6.913
EU - Europa 5.709
SA - Sud America 1.295
AF - Africa 157
OC - Oceania 22
Continente sconosciuto - Info sul continente non disponibili 16
Totale 22.441
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.054
SG - Singapore 3.081
CN - Cina 1.509
DE - Germania 1.401
IT - Italia 1.218
BR - Brasile 1.054
SE - Svezia 876
VN - Vietnam 724
FR - Francia 552
IE - Irlanda 304
IN - India 261
GB - Regno Unito 255
UA - Ucraina 253
FI - Finlandia 212
BD - Bangladesh 205
HK - Hong Kong 204
ID - Indonesia 196
JP - Giappone 188
CA - Canada 140
RU - Federazione Russa 133
AR - Argentina 107
TR - Turchia 96
PL - Polonia 93
NL - Olanda 87
IQ - Iraq 79
KR - Corea 66
MX - Messico 64
BE - Belgio 52
ZA - Sudafrica 52
ES - Italia 47
SA - Arabia Saudita 41
AT - Austria 38
PK - Pakistan 36
CZ - Repubblica Ceca 31
EC - Ecuador 31
IR - Iran 29
CH - Svizzera 24
LT - Lituania 23
PH - Filippine 23
AE - Emirati Arabi Uniti 22
CI - Costa d'Avorio 21
CO - Colombia 21
PE - Perù 19
PY - Paraguay 19
AU - Australia 18
UZ - Uzbekistan 18
EG - Egitto 17
IL - Israele 17
RO - Romania 17
JO - Giordania 16
CL - Cile 15
MA - Marocco 14
VE - Venezuela 14
NP - Nepal 13
GR - Grecia 11
JM - Giamaica 11
UY - Uruguay 11
AL - Albania 10
HN - Honduras 10
PT - Portogallo 10
CR - Costa Rica 9
EU - Europa 9
KE - Kenya 9
KZ - Kazakistan 9
MY - Malesia 9
SN - Senegal 9
ET - Etiopia 8
AZ - Azerbaigian 7
DZ - Algeria 7
KG - Kirghizistan 7
LB - Libano 7
PA - Panama 7
BH - Bahrain 6
DO - Repubblica Dominicana 6
HU - Ungheria 6
SI - Slovenia 6
SK - Slovacchia (Repubblica Slovacca) 6
SY - Repubblica araba siriana 6
TH - Thailandia 6
TZ - Tanzania 6
GT - Guatemala 5
MD - Moldavia 5
NO - Norvegia 5
TN - Tunisia 5
TT - Trinidad e Tobago 5
BG - Bulgaria 4
BY - Bielorussia 4
CY - Cipro 4
EE - Estonia 4
HR - Croazia 4
MK - Macedonia 4
NZ - Nuova Zelanda 4
OM - Oman 4
TW - Taiwan 4
A2 - ???statistics.table.value.countryCode.A2??? 3
BB - Barbados 3
DK - Danimarca 3
GE - Georgia 3
LA - Repubblica Popolare Democratica del Laos 3
LU - Lussemburgo 3
Totale 22.387
Salva come PNG Salva come JPEG
Città #
Singapore 1.773
San Jose 854
Chandler 848
Ashburn 839
Beijing 308
Dublin 300
New York 291
Ho Chi Minh City 262
Rome 256
Los Angeles 241
Dallas 211
Hong Kong 187
Hefei 186
The Dalles 183
Lauterbourg 182
Milan 174
Tokyo 174
Jakarta 171
San Mateo 150
Jacksonville 147
Hanoi 146
Chicago 131
Cattolica 125
Boston 118
Munich 116
Ann Arbor 115
St Louis 114
Council Bluffs 112
Frankfurt am Main 110
Wilmington 101
São Paulo 99
Nanjing 89
Marseille 88
Helsinki 85
Moscow 84
Boardman 81
Santa Clara 77
Buffalo 74
Princeton 73
Nürnberg 57
Kent 55
Seoul 55
Houston 53
Redwood City 53
Izmir 52
Turku 50
Warsaw 48
Brussels 47
Hyderabad 47
Paris 46
San Francisco 45
Zhengzhou 45
Orem 44
Da Nang 43
Dearborn 43
Lawrence 42
Nuremberg 42
Woodbridge 41
Atlanta 40
Seattle 39
Brooklyn 38
Amsterdam 37
Bremen 37
Montreal 37
Toronto 37
London 36
Denver 35
Fairfield 35
Stockholm 35
Phoenix 33
Shanghai 33
Augusta 32
Nanchang 32
Rio de Janeiro 31
Haiphong 30
Johannesburg 30
Baghdad 29
Lappeenranta 29
Tianjin 29
Guangzhou 28
Hangzhou 28
North Bergen 28
Pune 28
Chennai 26
Poplar 25
Shenyang 25
Belo Horizonte 23
Düsseldorf 23
Kraków 23
Manchester 22
Norwalk 22
Abidjan 21
Changsha 21
Hebei 20
Hải Dương 20
Lancaster 20
Porto Alegre 20
Guarulhos 19
Mumbai 19
Tukwila 19
Totale 11.777
Salva come PNG Salva come JPEG
Nome #
From small nodule to overt HCC: a multistep process of carcinogenesis as seen during surveillance 345
Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment 335
Gut Microbiota and Cardiovascular Disease: Evidence on the Metabolic and Inflammatory Background of a Complex Relationship 260
HepPar1-Positive Circulating Microparticles Are Increased in Subjects with Hepatocellular Carcinoma and Predict Early Recurrence after Liver Resection 242
Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcohol-associated liver disease 215
Something more to say about calcium homeostasis: the role of vitamin K2 in vascular calcification and osteoporosis 203
TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib 203
Biomarkers of low-grade inflammation in primary varicose veins of the lower limbs 200
Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications 193
Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development 192
Liver transplantation in patients with alcoholic liver disease: A retrospective study 192
Gemelli decision tree Algorithm to Predict the need for home monitoring or hospitalization of confirmed and unconfirmed COVID-19 patients (GAP-Covid19): preliminary results from a retrospective cohort study 191
Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound 191
Morphological and functional consequences of transradial coronary angiography on the radial artery: implications for its use as a bypass conduit 187
Intestinal barrier in human health and disease 183
Update on the Role of Rifaximin in Digestive Diseases 180
Early prediction of response to Sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound 177
New modalities of ultrasound-based intima-media thickness, arterial stiffness and non-coronary vascular calcifications detection to assess cardiovascular risk 176
Contrast-enhanced ultrasound in the short-term evaluation of hepatocellular carcinoma after locoregional treatment 176
Treatment of recurrent genotype 4 hepatitis C after liver transplantation: early virological response is predictive of sustained virological response. An AISF RECOLT-C group study 167
Improved gut microbiota features after the resolution of SARS‑CoV‑2 infection 167
Hug sign in intraprocedural cone-beam-CT to predict short-term response to combined treatment of hepatocellular carcinoma 166
Use and indications of cholestyramine and bile acid sequestrants 166
Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers 165
Something more to say about calcium homeostasis: the role of vitamin K2 in vascular calcification and osteoporosis. 165
TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib 161
HepatoCATT Study Group for the Multidisciplinary Management of HCC. Interventional oncology treatments for unresectable early stage HCC in patients with a high risk for intraprocedural bleeding: Is a single-step combined therapy safe and feasible? 159
Diagnosis of bowel diseases: the role of imaging and ultrasonography 158
Prevention and treatment of hepatic encephalopathy: focusing on gut microbiota 157
Diagnosis and treatment of small intestinal bacterial overgrowth 156
Gut microbiota and metabolic syndrome 155
The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin 155
Exploring the link: Porto-sinusoidal vascular disorder and inflammatory bowel disease - A comprehensive narrative review 154
Diet-Induced Alterations in Gut Microbiota Composition and Function 154
Project for interventional Oncology LArge-database in liveR Hepatocellular carcinoma - Preliminary CT-based radiomic analysis (POLAR Liver 1.1) 153
International consensus statement on microbiome testing in clinical practice 152
Intestinal Permeability and Dysbiosis in Female Patients with Recurrent Cystitis: A Pilot Study 152
The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma 149
Vaccine Responses in Patients with Liver Cirrhosis: From the Immune System to the Gut Microbiota 149
Reverse time-dependent effect of alphafetoprotein and disease control on survival of patients with Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma 149
Subclinical atherosclerosis is linked to small intestinal bacterial overgrowth via vitamin K2-dependent mechanisms 148
Management of Portal Hypertension in Patients with Hepatocellular Carcinoma on Systemic Treatment: Current Evidence and Future Perspectives 147
Interventional Oncology and Immuno-Oncology: Current Challenges and Future Trends 147
Skeletal Muscle Loss during Multikinase Inhibitors Therapy: Molecular Pathways, Clinical Implications, and Nutritional Challenges. 145
Effect of Low-Dose Alcohol Consumption on Chronic Liver Disease 144
Dynamics of liver stiffness predicts complications in patients with HCV related cirrhosis treated with direct-acting antivirals 144
High prevalence of lower limb atherosclerosis is linked with the gut–liver axis in patients with primary biliary cholangitis 143
The metabolic and toxicological considerations for mTOR inhibitors in the treatment of hepatocarcinoma 143
Physiology and pathophysiology of liver lipid metabolism 143
Critical analysis of major and ancillary features of LI-RADS v2018 in the differentiation of small (< 2 cm) hepatocellular carcinoma from dysplastic nodules with gadobenate dimeglumine-enhanced magnetic resonance imaging 141
Interventional oncology treatment for unresecable early stage HCC in patient with high risk for intraprocedural bleeding: is a single step combined therapy safe and feasible? 140
Nasopharyngeal Microbiota Profiling of SARS-CoV-2 Infected Patients 140
Use and indications of cholestyramine and bile acid sequestrants 139
Lynch Syndrome and Thyroid Nodules: A Single Center Experience 137
Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers 136
HEPATOCATT STUDY GROUP. Critical analysis of major and ancillary features of LI-RADS v2018 in the differentiation of small (≤ 2 cm) hepatocellular carcinoma from dysplastic nodules with gadobenate dimeglumine-enhanced magnetic resonance imaging. 136
Characterization of the gut-liver-muscle axis in cirrhotic patients with sarcopenia 135
Anticoagulants in cirrhotic patients: controversies and certainties in PVT management 134
Morphological and functional consequences of transradial coronary angiography on the radial artery: implications for its use as a bypass conduit 134
Safety of Anticoagulant Treatment in Patients With Splanchnic Vein Thrombosis and History of Portal Hypertension–Related Bleeding 133
Gut Dysbiosis and Fecal Calprotectin Predict Response to Immune Checkpoint Inhibitors in Patients With Hepatocellular Carcinoma 133
Mitochondria-Derived Vesicles, Sterile Inflammation, and Pyroptosis in Liver Cancer: Partners in Crime or Innocent Bystanders? 132
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept 132
Missed linkage to care for patients who screened positive for Hepatitis C in a tertiary care centre: Results of the Telepass project 131
Treatment of hepatitis C in compensated cirrhotic patients is equally effective before and after liver transplantation 130
Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers 128
Future Modulation of Gut Microbiota: From Eubiotics to FMT, Engineered Bacteria, and Phage Therapy 127
Hepatocellular Carcinoma is Associated with Gut Microbiota Profile and Inflammation in Non-Alcoholic Fatty Liver Disease 127
Multiparametric Dynamic Ultrasound Approach for Differential Diagnosis of Primary Liver Tumors 126
Is there a role for anticoagulants in portal vein thrombosis management in cirrhotic patients? 126
Balloon-Occluded Radiofrequency Ablation as Bridge to TACE in the Treatment of Advanced HCC with Arterioportal Shunt 125
The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence 124
Safety of Anticoagulant Treatment in Patients With Splanchnic Vein Thrombosis and History of Portal Hypertension–Related Bleeding 124
What we should know about portal vein thrombosis in cirrhotic patients: A changing perspective 124
Liver involvement is not associated with mortality: results from a large cohort of SARS-CoV-2-positive patients 124
Meta-Analysis: Inverse Association Between Helicobacter pylori Infection and Eosinophilic Oesophagitis 122
MetaLiverCat: the NAFLD/NASH multidisciplinary board at Fondazione Policlinico Gemelli IRCCS 121
Hepatocellular-Carcinoma-Derived Organoids: Innovation in Cancer Research 121
Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C 119
Radial Artery as a Coronary Artery Bypass Conduit: 20-Year Results 119
Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis: Case Reports 119
Safety of Anticoagulant Treatment in Patients With Splanchnic Vein Thrombosis and History of Portal Hypertension–Related Bleeding 118
Role of Akkermansia in Human Diseases: From Causation to Therapeutic Properties 118
Contrast-enhanced ultrasound patterns of hepatocellular adenoma: an Italian multicenter experience 118
Regorafenib: a promising treatment for hepatocellular carcinoma 118
Personalized Therapy in a Multidisciplinary Team Improves Survival in Patient with HCC: The Hepatocatt Experience 117
GUT MICROBIOTA IN PRIMARY SCLEROSING CHOLANGITIS: FROM PROGNOSTIC ROLE TO THERAPEUTIC IMPLICATIONS 117
Morphological and functional consequences of transradial coronary angiography on the radial artery: Implications for its use as a bypass conduit 117
Direct portal pressure gradient measurement in patients with porto-sinusoidal vascular disease 116
Functional hypothalamic amenorrhea: gut microbiota composition and the effects of exogenous estrogen administration 116
Gut microbiota modulation in patients with non-alcoholic fatty liver disease: Effects of current treatments and future strategies 115
A Real-World Analysis of the Population with Hepatitis C Virus Infection Affected by Type 2 Diabetes in Italy: Patients’ Characteristics, Comorbidity Profiles and Treatment Patterns 114
Durvalumab: an investigational agent for unresectable hepatocellular carcinoma 114
Minimal Hepatic Encephalopathy is Associated with Increased Cerebral Vascular Resistance. A Transcranial Doppler Ultrasound Study 113
Microvascular Thrombosis and Liver Fibrosis Progression: Mechanisms and Clinical Applications 113
“Pleiotropic” Effects of Antibiotics: New Modulators in Human Diseases 112
Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation 112
Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation 112
Increased Faecalibacterium abundance is associated with clinical improvement in patients receiving rifaximin treatment 112
Gut Microbiota and Infectious Complications in Advanced Chronic Liver Disease: Focus on Spontaneous Bacterial Peritonitis 111
Totale 14.976
Salva come PNG Salva come JPEG
Categoria #
all - tutte 97.082
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 97.082
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022957 75 51 17 65 64 32 14 181 38 62 183 175
2022/20232.545 306 288 180 360 146 332 142 247 295 55 110 84
2023/20241.664 91 413 70 86 73 253 116 37 27 88 164 246
2024/20253.718 92 87 307 90 284 132 152 175 445 475 841 638
2025/202610.340 1.355 343 695 1.150 1.725 471 1.805 517 715 713 492 359
2026/2027368 368 0 0 0 0 0 0 0 0 0 0 0
Totale 22.781